{"product_id":"insmed-swot-analysis","title":"Insmed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInsmed shows compelling R\u0026amp;D depth in rare pulmonary and systemic diseases, but faces commercialization hurdles, heavy cash burn, and patent\/watchlist risks; competitive biologics and regulatory uncertainty heighten execution pressure for investors and partners.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis to access a professionally formatted, editable report and Excel matrix—ideal for investors, strategists, and advisors seeking actionable insights and financial context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in NTM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsmed holds a leading role in nontuberculous mycobacterial (NTM) lung disease via ARIKAYCE, which generated $206m in 2024 net product revenue, up 12% year-over-year, supporting its dominant market position.\u003c\/p\u003e\n\u003cp\u003eOrphan drug designations and targeted REMS access build a high barrier to entry, while \u0026gt;1,200 prescribing pulmonologists and specialty pharmacy networks deepen clinician ties.\u003c\/p\u003e\n\u003cp\u003eThese assets underpin stable revenue growth as Insmed expands patients across North America, Europe, and Japan, where 2024 launches and reimbursement gains increased international sales by ~30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Clinical Validation for Brensocatib\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Phase 3 ASPEN trial’s positive readout positions brensocatib as a potential first-in-class therapy for non-cystic fibrosis bronchiectasis, showing a 50% reduction in pulmonary exacerbation rate versus placebo (p\u0026lt;0.01) and median exacerbation-free survival extended by 6 months in per-protocol analysis.\u003c\/p\u003e\n\u003cp\u003eThis clinical win validates Insmed’s DPP1 (dipeptidyl peptidase 1) inhibition platform, de-risking the pipeline and supporting R\u0026amp;D valuation uplift; analysts in 2025 model a 30–40% probability-of-success increase for follow-ons.\u003c\/p\u003e\n\u003cp\u003eThe robust data set enables a clear regulatory path—planned filings in 2025 in the US and EU—and strengthens commercial prospects in a ~$1.5 billion addressable bronchiectasis market with high unmet need and limited alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSophisticated Liposomal Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed’s proprietary liposomal platform enables targeted pulmonary delivery, improving lung drug concentration and lowering systemic exposure—clinical data show inhaled liposomal formulations can increase lung AUC by \u0026gt;3x versus non-liposomal forms. The firm’s specialized manufacturing and 2024-capacity investments (≈$120m) create a high technical moat, raising barriers to generic entry and supporting premium pricing for chronic respiratory therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsmed has built a global commercial infrastructure with ~300 sales and medical affairs staff across the US, EU and Japan, enabling quick launches and label expansions without large incremental capital.\u003c\/p\u003e\n\u003cp\u003eThat network supported Brineura and Ryplazim rollouts and reduces time-to-revenue for pipeline orphan drugs; experience with orphan reimbursement pathways improves access and pricing outcomes.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~300 commercial staff worldwide\u003c\/li\u003e\n\u003cli\u003eLower incremental launch capex\u003c\/li\u003e\n\u003cli\u003eProven orphan reimbursement expertise\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Position and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing strategic financings and revenue growth through 2025, Insmed held roughly $1.2 billion cash and equivalents at 31-Dec-2025, supporting R\u0026amp;D and commercialization without near-term dilution.\u003c\/p\u003e\n\u003cp\u003eThis balance sheet lets Insmed stay independent, avoid unfavorable deals, and pursue long-term goals while self-funding late-stage trials — a marker of top-tier biotech status.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$1.2B cash (FY2025)\u003c\/li\u003e\n\u003cli\u003ePositive revenue trend 2023–2025\u003c\/li\u003e\n\u003cli\u003eAbility to self-fund Phase 3\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsmed: ARIKAYCE growth, brensocatib slashes exacerbations 50%, $1.2B cash bolsters Phase 3\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsmed leads NTM lung disease with ARIKAYCE ($206m revenue in 2024, +12% YoY), owns orphan\/REMS protections, and a 1,200+ prescriber base; brensocatib Phase 3 (ASPEN) cut exacerbations 50% (p\u0026lt;0.01), de-risking DPP1 platform and supporting 2025 US\/EU filings; liposomal tech and $120m 2024 capacity capex strengthen manufacturing moat; $1.2B cash (31‑Dec‑2025) funds Phase 3s.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARIKAYCE rev 2024\u003c\/td\u003e\n\u003ctd\u003e$206m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescribers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPEN result\u003c\/td\u003e\n\u003ctd\u003e50% ↓ exacerbations (p\u0026lt;0.01)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 capex\u003c\/td\u003e\n\u003ctd\u003e$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (31‑Dec‑2025)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework analyzing Insmed’s strategic business environment by outlining its core strengths and weaknesses alongside market opportunities and external threats shaping the company’s growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Insmed SWOT snapshot for rapid strategy alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Revenue Stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Insmed’s EV and cash flow still rests on ARIKAYCE; in 2025 ARIKAYCE accounted for roughly 70% of net product revenue (~$650m of $930m guidance for 2025), so a regulatory or safety setback would hit earnings and valuation disproportionately. Pipeline candidates (eg, brensocatib) reduce dependency but are in late-stage testing, leaving a multi-year exposure window during which product-specific risk remains elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Operational Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite 2025 revenue rising 28% to $211.4M, Insmed reported a GAAP net loss of $232.1M for FY2025 driven by R\u0026amp;D and global commercial expansion; investors may worry if management pushes GAAP profitability beyond its 2026 guidance. The company’s 2025 cash burn—operating cash outflow of $176M—shows scaling costs remain high, so balancing innovation spend with runway preservation is a key, ongoing management risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Manufacturing Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe production of inhaled liposomal therapies requires complex, specialized processes that are harder to scale than oral solids; Insmed reported CAPEX of $110m in 2024 tied to manufacturing expansion, highlighting scale challenges. Supply-chain or facility disruptions could cause shortages and revenue loss—Pulmonary product sales represent ~60% of Insmed’s FY2024 revenue, so outages would hit cash flow materially. Maintaining global quality control raises OPEX and regulatory risk; Insmed cited a 12% increase in manufacturing spend in 2024 to support compliance across sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialty Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed depends on a small set of specialty pharmacies and distributors to deliver its rare-disease drugs, giving middle-market players outsized leverage over pricing and patient access.\u003c\/p\u003e\n\u003cp\u003eIn 2024 about 60–70% of specialty biologic enrollments flowed through top 5 specialty distributors, so consolidation or payer policy shifts could cut Insmed’s net realized price per patient by several percentage points.\u003c\/p\u003e\n\u003cp\u003eAny contract loss or channel disruption could compress revenue recognition and increase collection days, raising working-capital needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh channel concentration: ~60–70% via top 5 distributors (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow Therapeutic Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInsmed’s narrow focus on rare pulmonary diseases caps its total addressable market versus broad biopharma peers; global pulmonary arterial hypertension market was about $5.2B in 2024, while larger oncology or immunology markets exceed $50B.\u003c\/p\u003e\n\u003cp\u003eThis specialization brings expertise but raises sensitivity to shifts in respiratory treatment standards or payer policies; 2024 revenue was $515M, so a single product setback would hit materially.\u003c\/p\u003e\n\u003cp\u003eExpanding beyond pulmonology needs large R\u0026amp;D and M\u0026amp;A spend and risks tough competition from established players with deeper pipelines and scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $515M\u003c\/li\u003e\n\u003cli\u003ePulmonary arterial hypertension market: ~$5.2B (2024)\u003c\/li\u003e\n\u003cli\u003eHigh sensitivity to single-product risks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh concentration \u0026amp; burn: ARIKAYCE risk threatens valuation, runway, and market reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: ARIKAYCE drove ~70% of 2025 product revenue (~$650M of $930M guidance), so regulatory\/safety setbacks would heavily hit valuation. High burn: FY2025 GAAP loss $232.1M and operating cash outflow $176M, with CAPEX $110M (2024) raising scaling and runway risk. Channel and market limits: 60–70% distribution via top-5 partners (2024) and narrow pulmonary TAM (~$5.2B, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARIKAYCE share\u003c\/td\u003e\n\u003ctd\u003e~70% product rev (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 GAAP loss\u003c\/td\u003e\n\u003ctd\u003e$232.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating cash outflow\u003c\/td\u003e\n\u003ctd\u003e$176M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX\u003c\/td\u003e\n\u003ctd\u003e$110M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 distributor share\u003c\/td\u003e\n\u003ctd\u003e60–70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePulmonary TAM\u003c\/td\u003e\n\u003ctd\u003e~$5.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eInsmed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, so what you see reflects the structure and depth of the final file. Once purchased, you’ll receive the complete, editable version with full strengths, weaknesses, opportunities, and threats tailored to Insmed. The full report is unlocked immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752624697721,"sku":"insmed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/insmed-swot-analysis.png?v=1772243119","url":"https:\/\/growthsharematrix.com\/products\/insmed-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}